BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 18090053)

  • 1. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.
    Soulié C; Marcelin AG; Ghosn J; Amellal B; Assoumou L; Lambert S; Duvivier C; Costagliola D; Katlama C; Calvez V
    AIDS; 2007 Oct; 21(16):2243-5. PubMed ID: 18090053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-receptor switch during HAART is independent of virological success.
    Saracino A; Monno L; Cibelli DC; Punzi G; Brindicci G; Ladisa N; Tartaglia A; Lagioia A; Angarano G
    J Med Virol; 2009 Dec; 81(12):2036-44. PubMed ID: 19856465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
    Waters L; Mandalia S; Randell P; Wildfire A; Gazzard B; Moyle G
    Clin Infect Dis; 2008 May; 46(10):1617-23. PubMed ID: 18419499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.
    Delobel P; Nugeyre MT; Cazabat M; Sandres-Sauné K; Pasquier C; Cuzin L; Marchou B; Massip P; Cheynier R; Barré-Sinoussi F; Izopet J; Israël N
    J Virol; 2006 Oct; 80(20):10229-36. PubMed ID: 17005700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
    Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 co-receptor usage based on V3 loop sequence analysis: preferential suppression of CXCR4 virus post HAART?
    Jiao Y; Wang P; Zhang H; Zhang T; Zhang Y; Zhu H; Wu H
    Immunol Invest; 2011; 40(6):597-613. PubMed ID: 21513481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia.
    Spudich SS; Huang W; Nilsson AC; Petropoulos CJ; Liegler TJ; Whitcomb JM; Price RW
    J Infect Dis; 2005 Mar; 191(6):890-8. PubMed ID: 15717264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy.
    Equils O; Garratty E; Wei LS; Plaeger S; Tapia M; Deville J; Krogstad P; Sim MS; Nielsen K; Bryson YJ
    J Infect Dis; 2000 Sep; 182(3):751-7. PubMed ID: 10950768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast milk CD4+ T cells express high levels of C chemokine receptor 5 and CXC chemokine receptor 4 and are preserved in HIV-infected mothers receiving highly active antiretroviral therapy.
    Kourtis AP; Ibegbu CC; Theiler R; Xu YX; Bansil P; Jamieson DJ; Lindsay M; Butera S; Duerr A
    J Infect Dis; 2007 Apr; 195(7):965-72. PubMed ID: 17330786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epidemiology of HIV coreceptor tropism.
    Hoffmann C
    Eur J Med Res; 2007 Oct; 12(9):385-90. PubMed ID: 17933718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of HIV-1 RNA load after HAART interruption: relationship with CCR5 co-receptor density and proviral DNA load in HIV-infected patients.
    Soriano-Sarabia N; Vallejo A; Fernández G; Genebat M; Gutiérrez S; Muñoz-Fernández MA; Leal M
    J Clin Virol; 2007 Sep; 40(1):64-7. PubMed ID: 17662650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue.
    Grivel JC; Margolis LB
    Nat Med; 1999 Mar; 5(3):344-6. PubMed ID: 10086394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
    Blanco J; Barretina J; Clotet B; Esté JA
    J Leukoc Biol; 2004 Oct; 76(4):804-11. PubMed ID: 15258189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1.
    Bader J; Däumer M; Schöni-Affolter F; Böni J; Gorgievski-Hrisoho M; Martinetti G; Thielen A; Klimkait T;
    Clin Infect Dis; 2017 Feb; 64(3):295-300. PubMed ID: 27838645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia.
    Seclén E; Del Mar González M; De Mendoza C; Soriano V; Poveda E
    J Antimicrob Chemother; 2010 Jul; 65(7):1493-6. PubMed ID: 20488982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected coreceptor usage of primary human immunodeficiency virus type 1 isolates from viremic patients under highly active antiretroviral therapy.
    Holtkamp N; Otteken A; Findhammer S; Miller V; Kurth R; Werner A
    J Infect Dis; 2000 Feb; 181(2):513-21. PubMed ID: 10669334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure.
    Ferrer P; Tello M; Montecinos L; Tordecilla R; Rodríguez C; Beltrán C; Guzmán MA; Ferrés M; Pérez CM; Afani A
    J Clin Virol; 2014 Jul; 60(3):290-4. PubMed ID: 24793966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy.
    Ribeiro RM; Hazenberg MD; Perelson AS; Davenport MP
    J Virol; 2006 Jan; 80(2):802-9. PubMed ID: 16378982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups.
    Dornadula G; Nunnari G; Vanella M; Roman J; Babinchak T; DeSimone J; Stern J; Braffman M; Zhang H; Pomerantz RJ
    J Infect Dis; 2001 Jun; 183(11):1682-7. PubMed ID: 11343220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.